TYRA-300 Phase 2 clinical trial data releases - objective response rates (ORR), progression-free survival (PFS), and safety profile versus existing FGFR3 inhibitors in bladder cancer patients
FDA regulatory milestones - IND clearances for new indications, breakthrough therapy designation potential, or accelerated approval pathway eligibility
Partnership/licensing announcements with major pharma for co-development or commercialization rights (typical deals: $50-200M upfront + milestones)
Competitive landscape shifts - rival FGFR inhibitor trial failures/successes (Janssen's erdafitinib, Incyte's pemigatinib, Blueprint's fisogatinib)
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D spending continues regardless of economic conditions, and cancer treatment demand is non-discretionary. However, financing environment sensitivity is high: risk-off markets reduce IPO/follow-on offering viability and compress biotech valuations. The 131% one-year return reflects 2025's biotech rally amid improved risk appetite.
High sensitivity through valuation mechanism rather than operations. Pre-revenue biotechs are discounted cash flow stories with payoffs 5-10 years out; rising rates increase discount rates and compress NPV of future drug sales. The 10-year Treasury yield directly impacts biotech sector multiples - the 2022 rate spike crushed biotech indices 40-60%. Additionally, higher rates increase opportunity cost of holding cash-burning equities versus risk-free alternatives. Operationally, interest income on cash balances provides minor offset (~5% on $170M = $8.5M annually at current rates).
Binary clinical trial risk - Phase 2/3 failure rates exceed 60% in oncology; single negative readout could eliminate 50-80% of market value overnight
Competitive obsolescence risk - Next-generation FGFR inhibitors or alternative mechanisms (antibody-drug conjugates, cell therapies) could render small molecule approach less attractive before commercialization
Regulatory pathway uncertainty - FDA approval standards for FGFR inhibitors evolving; accelerated approval may require confirmatory trials with years of additional investment
growth/momentum - Pure speculation on binary clinical outcomes attracts high-risk tolerance investors seeking 3-10x returns on successful drug approval. The 171% six-month surge indicates strong momentum trader presence. Institutional ownership likely concentrated in specialized healthcare/biotech funds (Perceptive Advisors, RTW Investments, RA Capital) rather than broad index funds. Minimal dividend/value investor interest given zero cash generation and negative ROE/ROA.
Trend
+2.9% vs SMA 50 · +54.2% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $0 | — | -$1.98 | — | ±4% | High8 |
FY2026(current) | $687429 $687429–$687429 | — | -$2.60 | — | ±11% | High10 |
FY2027 | $7.2M $7.2M–$7.2M | ▲ +950.6% | -$2.89 | — | ±14% | High9 |
INSTITUTIONAL OWNERSHIP
TYRA News
About
No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
TYRA◀ | $37.04 | +0.88% | $2.2B | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.42% | — | 50.3 | +398824.8% | -4085.6% | 1500 |